Letterpenny
2 월 전
Like I said. Gleeson is another car salesman. Another piece of shit fund manager. A glorified broker. I can smell them a mile away. Fucking scum bags. “ He was also Senior Vice President and Venture Partner with MDS Capital Corp. (now Lumira), where he was lead partner on a fund with more than $250 million under management focused on creating drug discovery companies based on novel Canadian science. Prior to his tenure with MDS, he enjoyed a 17-year operational career with ICl plc (now AstraZeneca), a global chemicals, pharmaceuticals, and advanced materials company, during which he was involved in technology commercialization in several fields both in Canada and internationally.”
People. Do your research. Satellos is next in line to merge with whatever controlled company they start up or maybe with Cytovia or Naya. I still think Naya. But it could be Immunis. I will keep ringing the siren for all who dare to listen to crazy K. I tell you now. Number one thing to do is check the CEO’s history. You will learn quickly how much of a scum bag the person is. They get paid to restructure and reorganize and recapitalize. They get paid to fuck with your money. Satellos will not exist for long. It will disappear. I don’t need to buy a damn thing as I know I already own these paid bitches without even lifting a finger. Watch and learn.
Dapper1
3 년 전
Newsfile Corp.
Thu, July 8, 2021, 5:11 PM
--------
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") is pleased to announce that the Company has received formal conditional approval from the TSX Venture Exchange (the "Exchange") of iCo's proposed business combination (the "Transaction") with Satellos Bioscience Inc. ("Satellos").
The Company has filed an information circular on SEDAR (the "Circular") that describes the Transaction in detail and will be mailing the Circular to shareholders on or about July 13, 2021. iCo has set August 3, 2021 as the date of the special meeting of shareholders of the Company to approve the Transaction, in accordance with the rules of the Exchange. The shareholder meeting is more fully described in the Circular.
In connection with the Transaction, iCo previously announced, on April 27, 2021, the successful closing of a private placement (the "Financing") of 85,294,117 subscription receipts (the "Subscription Receipts") at a price of $0.085 per Subscription Receipt for aggregate gross proceeds of approximately C$7.25 million, conditional upon successful closing of the Transaction. The Subscription Receipts will convert into common shares of iCo following the satisfaction of the escrow release conditions attached to the Subscription Receipts.
--------
Finally, iCo announces that if the Transaction is approved by iCo and Satellos shareholders, the Company expects trading of the shares of the combined company to begin trading on the Exchange as Satellos Bioscience Inc. under the symbol MSCL during the week of August 9, 2021.
Jabramowitz
5 년 전
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
8:01 am ET April 15, 2020 (Newsfile) Print
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") announced today the successful results of a Phase 1b clinical study of iCo's Oral Amphotericen B Delivery System ("Amp B" or "iCo 019") which began on December 9, 2019. The purpose of the study was to evaluate the safety, tolerability and pharmacokinetics of 100mg and 400mg doses of iCo 019.
iCo also announced the appointment of Dr. Kishor Wasan as Director of Research for the Company. Dr. Wasan has received numerous awards for his contributions to health sciences including the Canadian Society of Pharmaceutical Sciences Leadership award for outstanding contributions to Pharmaceutical Sciences in Canada and is a Fellow of the Canadian Academy of Health Sciences and the American Association of Pharmaceutical Scientists. Dr. Wasan has published over 240 peer-reviewed articles and 280 abstracts in the area of lipid-based drug delivery and lipoprotein-drug interactions. Most recently, Dr. Wasan served as the Dean of the College of Pharmacy and Nutrition of the University of Saskatchewan from August 2014 to June 2019. Dr. Wasan led the research team at the Wasan lab at the University of British Columbia that developed what has become iCo 019, and will initially focus his efforts on the further development of iCo 019 via partnerships and collaborations. "We are delighted to have Kish formally onboard leading our research efforts. We've worked with him since the founding of the Company and will benefit from his proven research abilities and deep connectivity to the global pharmaceutical industry," noted William Jarosz, the CEO of iCo.
Commenting on the iCo 019 trial Dr. Wasan noted, "In the Phase Ib human clinical study all repeated doses of ICO-019 were well tolerated with no serious adverse events including no signs of GI, kidney or liver toxicities. ICO-019 at the 100 mg dose achieved a median plasma Cmax of 25 ng AmB/mL and AUC (0-inf) 990 hr* ng/mL after day 1 of dosing and a median plasma Cmax of 44 ng AmB/mL and AUC (0-inf) 1998 hr*ng/mL after 10 day of dosing. This approximate doubling of the AUC (0-inf) measure between day 1 and day 10 was observed not only at the 100 mg dose but at the 400 mg dose as well.
These data suggest that we may have developed a novel oral amphotericin B formulation that is safe and tolerable following multiple dosing to healthy human subjects. In addition, the increased AUC observed in the phase 1b human clinical studies between the day 1 of dosing to the day 10 of dosing suggests that iCO-19 formulation has the ability to increase and sustain Amphotericin B tissue concentrations within infected tissues without the associated GI, liver or kidney toxicity. I am pleased with the PK results from the Phase 1b trial."
In addition, iCo announced it will delay the start of the anticipated Phase 2 trial of iCo 019 as the result of uncertainty generated by the current COVID-19 events. "We are concerned that the ongoing pandemic could cause clinical challenges affecting our trial's timeline, leading to longer than expected delays and higher costs. Despite the positive findings of our Phase 1b trial, we believe it is the best use of our resources, and the resouces of our clinical research partners in the current environment, to delay the start of the Phase 2 trial until we have more clarity regarding the course of COVID-19 and its effect on clinical trial practices," stated Mr Jarosz.
Jabramowitz
5 년 전
iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing and Follow Up
8:02 am ET February 10, 2020 (Newsfile) Print
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in its Phase 1b study have received doses of Oral Amphotericin B (either 100mg and 400mg/day) over ten days and, subsequent to dosing, have been followed up for an additional ten days. Full results of the Phase 1b study are currently expected before the end of Q1 2020.
Stated Dr. Peter Hnik, Chief Medical Officer of iCo, "Results from the Phase 1b study using multiple ascending doses of oral Amphotericin B will provide additional safety and pharmacokinetic information needed for the upcoming Phase 2 clinical study in patients with vulvovaginal candidiasis ("VVC").
According to Denning et al, "Worldwide, recurrent vulvovaginal candidiasis affects about 138 million women annually (range 103-172 million), with a global annual prevalence of 3871 per 100?000 women; 372 million women are affected by recurrent vulvovaginal candidiasis over their lifetime. The 25-34 year age group has the highest prevalence (9%). By 2030, the population of women with recurrent vulvovaginal candidiasis each year is estimated to increase to almost 158 million, resulting in 20,240,664 extra cases with current trends using base case estimates in parallel with an estimated growth in females from 3·34 billion to 4·181 billion. In high-income countries, the economic burden from lost productivity could be up to US$14·39 billion annually."*
A Phase 2 study comparing oral Amphotericin B to fluconazole in a head-to-head study in vulvovaginal candidiasis is currently expected to commence in Q2 2020.
A number of additional indications, that may also be difficult and impractical to treat using intravenous formulation, are expected to be explored (active treatment and prevention) in the near future.
iCo also announces that the Company has also engaged Proconsul Capital ("Proconsul") for investor relations activities. Proconsul will be paid $8,000 CDN, excluding taxes, on a month-to-month basis.
Jabramowitz
5 년 전
iCo Therapeutics Announces Completion of Sub-license Transfer and Full Dosing of Fifty Per Cent of Phase 1b Subjects
8:03 am ET December 24, 2019 (Newsfile) Print
Vancouver, British Columbia--(Newsfile Corp. - December 24, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in the first of two cohorts in its Phase 1b study have received 100 mg doses of Oral Amphotericin B on a daily basis over ten days, with no drug-related adverse events observed to date. One additional cohort is expected to be dosed in early Q1 2020, followed by the initiation of a Phase II study comparing oral Amphotericin B to fluconazole in a head-to-head study in vulvovaginal candidiasis in Q2 2020.
iCo also announces the completion of the transfer of its sub-license of iCo-008, an antibody targeting eotaxin-1, with the receipt of an assignment and assumption acknowledgement from its new biotechnology partner with a market capitalization in excess of $24 billion USD. Furthermore, iCo has communicated to its pharmaceutical partner, which previously licensed iCo-008 worldwide exclusive to iCo, the completion of said sub-license transfer in its annual report.
Hot Features
프리미엄
실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
AJ Freely
1 년 전
Renee
3 년 전
Mikefbi
4 년 전
